[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @Heatlamp11 Lidopete Lidopete posts on X about $mreo, $rare, ai, $ctmx the most. They currently have XXX followers and XXX posts still getting attention that total XXX engagements in the last XX hours. ### Engagements: XXX [#](/creator/twitter::27276246/interactions)  - X Week XXXXX +11% - X Month XXXXXX -XX% - X Months XXXXXX +667% - X Year XXXXXXX +553% ### Mentions: X [#](/creator/twitter::27276246/posts_active)  - X Week X -XX% - X Month XX +17% - X Months XXX +338% - X Year XXX +732% ### Followers: XXX [#](/creator/twitter::27276246/followers)  - X Week XXX +0.76% - X Month XXX +4.50% - X Months XXX +33% - X Year XXX +48% ### CreatorRank: XXXXXXXXX [#](/creator/twitter::27276246/influencer_rank)  ### Social Influence **Social category influence** [cryptocurrencies](/list/cryptocurrencies) [finance](/list/finance) [currencies](/list/currencies) **Social topic influence** [$mreo](/topic/$mreo) #4, [$rare](/topic/$rare) #8, [ai](/topic/ai), [$ctmx](/topic/$ctmx), [$medp](/topic/$medp), [icon](/topic/icon), [no bs](/topic/no-bs), [imo](/topic/imo), [q4](/topic/q4), [strong](/topic/strong) **Top accounts mentioned or mentioned by** [@jfais20](/creator/undefined) [@joepickens2007](/creator/undefined) [@semodough](/creator/undefined) [@feldtinvesting](/creator/undefined) [@uchi_wawa](/creator/undefined) [@revshark](/creator/undefined) [@bioluck80](/creator/undefined) [@oncinvestor](/creator/undefined) [@cryptobiotech](/creator/undefined) [@srqstockpicker](/creator/undefined) [@foxesthrufences](/creator/undefined) [@quantumup1](/creator/undefined) [@johnzidar](/creator/undefined) [@persimmonti](/creator/undefined) [@thefortunetell5](/creator/undefined) [@medstudentinvst](/creator/undefined) [@darrenestes](/creator/undefined) [@andrews87261985](/creator/undefined) [@s6m6w6on](/creator/undefined) [@ditullioluigi](/creator/undefined) **Top assets mentioned** [SuperRare (RARE)](/topic/$rare) [Medpace Holdings, Inc. Common Stock (MEDP)](/topic/$medp) ### Top Social Posts Top posts by engagements in the last XX hours "$MREO $RARE FDA shift in drug study requirements sends trial runners lower Fly Intel Jessica de Sa-Mota - email While exceptions will require two trials the default framework is expected to shift toward a single pivotal study according to media reports Shares of companies that conduct drug trials on behalf of pharmaceutical companies such as Icon (ICLR) Iqvia (IQV) and Medpace (MEDP) are trading lower following a media report stating the Food and Drug Administration is planning to reduce the number of trials required for many drug approvals. ONLY ONE CLINICAL STUDY: The FDA plans to generally" [X Link](https://x.com/Heatlamp11/status/1996931157452103899) 2025-12-05T13:14Z XXX followers, XXX engagements "$MREO $RARE Following is my conversation with GROK in reference to my belief that setrusumab will be granted FDA approval. (no bs imo): --------------------------------------- I believe the phase X odds for approval of MREO's drug setusumab are very high based on the following: The anecdotes quoted by the CMO of RARE. The real-life examples of a higher quality of life of O.I. children and patients are strong. The world of biotechs is filled with companies' management over hyping their drug opportunities but this feels different and I will be shocked if he is lying. Every analyst has extremely" [X Link](https://x.com/Heatlamp11/status/1997265789364146320) 2025-12-06T11:24Z XXX followers, 1059 engagements "$MREO $RARE A.I. Upon FDA approval timelines for first deliveries of the drug: Overall the soonest widespread delivery is Q4 2026 with first doses potentially in October 2026 for eligible patients via expanded access or early shipments. Monitor Q4 2025 earnings for updates. Timeline for Setrusumab Delivery Post-FDA Approval. Mereo BioPharma (MREO) in partnership with Ultragenyx (RARE) is developing setrusumab (UX143) for osteogenesis imperfecta (OI). As of December X 2025 Phase X top-line data from the ORBIT and COSMIC trials are expected "around the end of 2025" (likely Q4 2025 per" [X Link](https://x.com/Heatlamp11/status/1997406591776403839) 2025-12-06T20:43Z XXX followers, 1128 engagements "A.I. $CTMX Is there anything to imply that JANX's problem could be CTMX's problem CytomXs main CRC asset is CX2051 a masked EpCAMtargeted ADC and so far the data look meaningfully positive for lateline metastatic CRC but with some emerging safety questions that investors need to track. The key Januxlike risk for CTMX is that larger less selected phase 1/2 datasets in broader CRC populations could dilute the current response rate and surface more safety events which would hit sentiment "but there is nothing yet to suggest a dramatic efficacy disappointment; if anything current mCRC activity" [X Link](https://x.com/Heatlamp11/status/1996230762228506817) 2025-12-03T14:51Z XXX followers, XXX engagements "A.I. $MREO & $RARE may have strong patent protection for setrusumab until 2046. This has a potentially profound positive impact on MREO's valuation going forward" [X Link](https://x.com/Heatlamp11/status/1994331142657294643) 2025-11-28T09:02Z XXX followers, XXX engagements "$MREO $RARE THE UK WILL RAISE PRICES PAID FOR NEW MEDICINES BY XX% AND CAP VPAG REBATES WHILE THE US AGREES NOT TO IMPOSE TARIFFS ON UK-MADE DRUGS AND PAUSES FUTURE PRICING INVESTIGATIONS. US OFFICIALS SAY THE DEAL WILL REDUCE THE BURDEN ON AMERICAN PATIENTS BOOST PHARMA INVESTMENT AND REBALANCE LONG-STANDING PRICING GAPS BETWEEN THE TWO COUNTRIES" [X Link](https://x.com/Heatlamp11/status/1995567744960344477) 2025-12-01T18:56Z XXX followers, XXX engagements "@TedKaridis @ShaunZanganeh24 Nobody has Emil's creds. With the approval of setrusumab on a percentage basis which will raise faster MREO or RARE" [X Link](https://x.com/Heatlamp11/status/1997678795164430512) 2025-12-07T14:45Z XXX followers, XXX engagements "$CTMX A.I. Benefits from Below==== The FDA's potential requirement for new CAR-T cancer treatments to prove superiority negatively affects small-cap cancer stocks with early-stage "off-the-shelf" allogeneic CAR-T therapies still in clinical trials as it raises the regulatory and cost burden. It potentially helps companies with existing approved CAR-T therapies (often larger biotechs/pharmas like Gilead or Bristol Myers Squibb) by reinforcing their market position and companies developing treatments that are fundamentally different from traditional CAR-T therapies such as T-cell engagers or" [X Link](https://x.com/Heatlamp11/status/1998303499319210120) 2025-12-09T08:07Z XXX followers, XX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@Heatlamp11 Lidopete
Lidopete posts on X about $mreo, $rare, ai, $ctmx the most. They currently have XXX followers and XXX posts still getting attention that total XXX engagements in the last XX hours.
Engagements: XXX #
- X Week XXXXX +11%
- X Month XXXXXX -XX%
- X Months XXXXXX +667%
- X Year XXXXXXX +553%
Mentions: X #
- X Week X -XX%
- X Month XX +17%
- X Months XXX +338%
- X Year XXX +732%
Followers: XXX #
- X Week XXX +0.76%
- X Month XXX +4.50%
- X Months XXX +33%
- X Year XXX +48%
CreatorRank: XXXXXXXXX #
Social Influence
Social category influence cryptocurrencies finance currencies
Social topic influence $mreo #4, $rare #8, ai, $ctmx, $medp, icon, no bs, imo, q4, strong
Top accounts mentioned or mentioned by @jfais20 @joepickens2007 @semodough @feldtinvesting @uchi_wawa @revshark @bioluck80 @oncinvestor @cryptobiotech @srqstockpicker @foxesthrufences @quantumup1 @johnzidar @persimmonti @thefortunetell5 @medstudentinvst @darrenestes @andrews87261985 @s6m6w6on @ditullioluigi
Top assets mentioned SuperRare (RARE) Medpace Holdings, Inc. Common Stock (MEDP)
Top Social Posts
Top posts by engagements in the last XX hours
"$MREO $RARE FDA shift in drug study requirements sends trial runners lower Fly Intel Jessica de Sa-Mota - email While exceptions will require two trials the default framework is expected to shift toward a single pivotal study according to media reports Shares of companies that conduct drug trials on behalf of pharmaceutical companies such as Icon (ICLR) Iqvia (IQV) and Medpace (MEDP) are trading lower following a media report stating the Food and Drug Administration is planning to reduce the number of trials required for many drug approvals. ONLY ONE CLINICAL STUDY: The FDA plans to generally"
X Link 2025-12-05T13:14Z XXX followers, XXX engagements
"$MREO $RARE Following is my conversation with GROK in reference to my belief that setrusumab will be granted FDA approval. (no bs imo): --------------------------------------- I believe the phase X odds for approval of MREO's drug setusumab are very high based on the following: The anecdotes quoted by the CMO of RARE. The real-life examples of a higher quality of life of O.I. children and patients are strong. The world of biotechs is filled with companies' management over hyping their drug opportunities but this feels different and I will be shocked if he is lying. Every analyst has extremely"
X Link 2025-12-06T11:24Z XXX followers, 1059 engagements
"$MREO $RARE A.I. Upon FDA approval timelines for first deliveries of the drug: Overall the soonest widespread delivery is Q4 2026 with first doses potentially in October 2026 for eligible patients via expanded access or early shipments. Monitor Q4 2025 earnings for updates. Timeline for Setrusumab Delivery Post-FDA Approval. Mereo BioPharma (MREO) in partnership with Ultragenyx (RARE) is developing setrusumab (UX143) for osteogenesis imperfecta (OI). As of December X 2025 Phase X top-line data from the ORBIT and COSMIC trials are expected "around the end of 2025" (likely Q4 2025 per"
X Link 2025-12-06T20:43Z XXX followers, 1128 engagements
"A.I. $CTMX Is there anything to imply that JANX's problem could be CTMX's problem CytomXs main CRC asset is CX2051 a masked EpCAMtargeted ADC and so far the data look meaningfully positive for lateline metastatic CRC but with some emerging safety questions that investors need to track. The key Januxlike risk for CTMX is that larger less selected phase 1/2 datasets in broader CRC populations could dilute the current response rate and surface more safety events which would hit sentiment "but there is nothing yet to suggest a dramatic efficacy disappointment; if anything current mCRC activity"
X Link 2025-12-03T14:51Z XXX followers, XXX engagements
"A.I. $MREO & $RARE may have strong patent protection for setrusumab until 2046. This has a potentially profound positive impact on MREO's valuation going forward"
X Link 2025-11-28T09:02Z XXX followers, XXX engagements
"$MREO $RARE THE UK WILL RAISE PRICES PAID FOR NEW MEDICINES BY XX% AND CAP VPAG REBATES WHILE THE US AGREES NOT TO IMPOSE TARIFFS ON UK-MADE DRUGS AND PAUSES FUTURE PRICING INVESTIGATIONS. US OFFICIALS SAY THE DEAL WILL REDUCE THE BURDEN ON AMERICAN PATIENTS BOOST PHARMA INVESTMENT AND REBALANCE LONG-STANDING PRICING GAPS BETWEEN THE TWO COUNTRIES"
X Link 2025-12-01T18:56Z XXX followers, XXX engagements
"@TedKaridis @ShaunZanganeh24 Nobody has Emil's creds. With the approval of setrusumab on a percentage basis which will raise faster MREO or RARE"
X Link 2025-12-07T14:45Z XXX followers, XXX engagements
"$CTMX A.I. Benefits from Below==== The FDA's potential requirement for new CAR-T cancer treatments to prove superiority negatively affects small-cap cancer stocks with early-stage "off-the-shelf" allogeneic CAR-T therapies still in clinical trials as it raises the regulatory and cost burden. It potentially helps companies with existing approved CAR-T therapies (often larger biotechs/pharmas like Gilead or Bristol Myers Squibb) by reinforcing their market position and companies developing treatments that are fundamentally different from traditional CAR-T therapies such as T-cell engagers or"
X Link 2025-12-09T08:07Z XXX followers, XX engagements